Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) gapped down prior to trading on Tuesday . The stock had previously closed at $1.04, but opened at $1.22. Aerpio Pharmaceuticals shares last traded at $1.13, with a volume of 2374687 shares trading hands.

ARPO has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating on shares of Aerpio Pharmaceuticals in a report on Wednesday, March 6th. Cantor Fitzgerald started coverage on Aerpio Pharmaceuticals in a report on Friday, January 18th. They set an “overweight” rating and a $8.00 price target for the company. Guggenheim downgraded Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday. Finally, National Securities downgraded Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $8.25.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01.

In other Aerpio Pharmaceuticals news, Director Muneer A. Satter acquired 63,818 shares of the business’s stock in a transaction on Thursday, January 10th. The stock was purchased at an average price of $2.35 per share, for a total transaction of $149,972.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Muneer A. Satter acquired 60,000 shares of the business’s stock in a transaction on Thursday, December 27th. The stock was acquired at an average price of $1.74 per share, with a total value of $104,400.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 303,818 shares of company stock valued at $604,772. Corporate insiders own 38.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Sphera Funds Management LTD. increased its position in shares of Aerpio Pharmaceuticals by 2.6% in the third quarter. Sphera Funds Management LTD. now owns 1,131,819 shares of the company’s stock valued at $3,497,000 after buying an additional 28,265 shares in the last quarter. Vanguard Group Inc. purchased a new position in shares of Aerpio Pharmaceuticals in the third quarter valued at $3,331,000. Vanguard Group Inc purchased a new position in shares of Aerpio Pharmaceuticals in the third quarter valued at $3,331,000. Acadian Asset Management LLC purchased a new position in shares of Aerpio Pharmaceuticals in the fourth quarter valued at $28,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Aerpio Pharmaceuticals in the fourth quarter valued at $36,000. Hedge funds and other institutional investors own 0.37% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/aerpio-pharmaceuticals-arpo-shares-gap-down-to-1-22/2902476.html.

About Aerpio Pharmaceuticals (OTCMKTS:ARPO)

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Featured Story: Trading Ex-Dividend

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.